UNSPSC 51311802: Bilastine

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PA1123N395. European Medicines Agency schedules Bilastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB37845. Bilastine generally arises in the molecular formula C28H37N3O3. The term BILASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, no. 3, 2000, list 44.) Most nations schedule bilastine under HS 29333999 and SITC 51574.

As of Q4 2014, BILASTINE remains the US FDA Preferred Term for this commodity. Bilastine bears US NLM identifiers UMLS ID C1101148 and NCI Concept Code C73045. SMILES: O(CCN1C(NC2C1CCCC2)C1CCN(CC1)CCC1CCC(C(C)(C)C(=O)O)CC1)CC.

UNSPSC 51311802 Bilastine is a Commodity-tier code representing antihistamine pharmaceuticals, though recent state and local solicitations tagged under this code reflect broader pharmaceutical procurement activity spanning naloxone, generic multi-source drugs, and over-the-counter products rather than bilastine specifically. State and local governments use this code to solicit pharmaceutical supplies for community health programs, hospital systems, and employee health benefit programs. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The Seminole County, Florida IFB for naloxone and drug deactivation systems exemplifies county-level procurement for opioid-response initiatives, while the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescriptions signals state-agency exploration of alternative pharmacy benefit models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic pharmaceuticals and OTC products demonstrates the growing role of cooperative purchasing vehicles in aggregating demand across multiple jurisdictions and states.

Recent activity spans Florida, Texas, and Minnesota-based cooperative membership. The most prominent recent opportunity is the MMCAP RFP (S1070000015802), issued January 20, 2026, with proposals due March 26, 2026, seeking manufacturers of generic multi-source pharmaceuticals and OTC products for distribution through three authorized wholesalers, with evaluation weighted 75 percent on price competitiveness and compliance with cGMP and Drug Supply Chain Security Act requirements. Seminole County's IFB 60459723LAS, posted June 30, 2026, procures 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023. The Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, gathers vendor capability information on direct-to-manufacturer prescription programs as a precursor to formal RFP development. These solicitations indicate active state and local demand for pharmaceutical supply chain optimization and community health product procurement, with multistate cooperatives serving as primary aggregation vehicles for routine generic and OTC sourcing.